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Transcripting factors modulating angiotensinogen gene expression in
hepatocytes. The gene encoding angiotensinogen is regulated at the
transcriptional level in hepatocytes in response to glucocorticoids and
inflammatory cytokines (IL-i and TNF). These hormones activate tran-
scription of the angiotensinogen gene by changing the abundance of DNA
binding proteins that interact with a multihormone-inducible enhancer
located between nucleotides —615 to —440 upstream of the major
transcription start site. Activation of this enhancer in hepatocytes is
effected by glucocorticoid- and cytokine-inducible DNA binding proteins.
Cytokine induction is mediated through the interaction of two classes of
transcription factors that bind to the acute-phase response element
(APRE): nuclear factor-KB (NF-B), and CCAAT-Box/Enhancer Binding
Protein (C/EBP). NF-KB is a multiprotein DNA binding complex seques-
tered in the cytoplasm that is induced in the nucleus by cytokines, whereas
C/EBP is a nuclear transcription factor family implicated in the expression
of differentiated hepatic proteins. During the acute-phase response,
individual C/EBP family members are discordinately regulated: C/EBPa
levels fall, whereas another CIEBP family member termed nuclear factor
1L6 (NF-1L6), is induced. We investigated the interaction between the two
acute-phase induced APRE-binding proteins: NF-KB and NF-1L6. Both
proteins bind to overlapping nucleotides in a mutually exclusive fashion
with similar affinities for the APRE. NF-1L6, a less potent transactivator,
attenuates NF-KB mediated transcription late in the evolution of the
acute-phase response. These observations argue for a temporal model of
sequentially-expressed transcription factors occupying the APRE during
the evolution of the inflammatory process.
Inducible hepatic expression of angiotensinogen, the precursor
of the potent vasopressor angiotensin II, is activated by steroid
hormones [1—3] and acute-phase inflammation [4—6]. Nuclear
run-on and gene transfer studies indicate that increases in angio-
tensinogen expression in response to these stimuli occurs at the
transcriptional level.
Using gene transfer studies we have previously reported the
cis-acting regulatory elements that mediate glucocorticoid activa-
tion of the angiotensinogen promoter [2, 7, 8]. The two identified
glucocorticoid response elements include GRE I, a consensus 15
base pair element containing the sequence 5'-AGAACATVIT-
GTTTC-3' between nt —584 to —570, and GRE II, a GRE 'half
site' containing the sequence 5'-AGAACA-3' between nt —477 to
—472. Site-directed mutations indicate that GRE I is essential for
glucocorticoid activation. In contrast, mutation of GRE II atten-
uates, but does not abolish, steroid activation, Individually, each
element confers glucocorticoid induction onto a heterologous
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promoter, demonstrating enhancer activity. That the glucocorti-
coid effect is dose-dependent, saturable and antagonized by the
antiglucocorticoid RU486 argues that the transcriptional effect is
mediated by the glucocorticoid receptor. Indeed, both GREs are
recognized by recombinant glucocorticoid receptor by gel shift
analysis. This hierarchic nature of GREs within the angiotensino-
gen gene is similar to arrangements in other hepatic genes, such as
the tyrosine aminotransferase gene [9].
During these studies, we also identified a critical cis element
located between nt —531 and —557, termed the acute-phase
response element (APRE), that mediates cytokine induction of
angiotensinogen gene expression. The APRE contains the se-
quence 5'-AGTTGGGATT'FCCAACC-3' and is recognized by
two different classes of DNA-binding proteins. Each class is itself
regulated in abundance as a function of acute-phase inflamma-
tion.
Results and Discussion
Two classes of transcription factors bind the APRE
Identification of the DNA-binding proteins that interact with
the APRE was approached by gel mobility shift assays of purified
nuclear proteins harvested from lipopolysaccharide (LPS)-stimu-
lated rat liver. By ion exchange and gel filtration chromatography,
an LPS-inducible protein, termed BPi, could be fractionated from
a family of heat stable nuclear proteins termed BPc [5].
We demonstrated that the BPI proteins includes members of
the nuclear factor-KB (NF-KB) family. The NF-KB/Rel,Dorsal
(NRD) transcription factors constitute a family by virtue of
containing a highly conserved DNA-binding Rel homology do-
main in their N-termini [10]. NF-KB members include the 50 kDa
protein termed p50, a DNA-binding subunit, and a 65 kDa
protein, termed p65, that contains weak DNA-binding activity and
is a potent transactivator. NF-KB p65:pSO heterodimers are
sequestered in the cytoplasm via interaction with an inhibitor
termed 1kB. Upon cytokine stimulation of hepatocytes, the NF-KB
p65:pSO heterodimer is released from 1kB binding and enters the
nucleus where it binds the APRE and stimulates transcription.
Evidence that BPi is NF-KB includes: cross competition of BPi-
APRE binding using NF-KB containing oligonucleotide probes,
similar methylation interference patterns of BPi and purified
NF-KB from bovine spleen, and detection of sequestered BPi
DNA-binding activity in the cytoplasm of unstimulated hepato-
cytes. Although we used UV cross linking to couple the NF-KB
p50 protein subunit to the APRE, demonstration that NF-KB p65,
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Fig. 1. (A) NF-1L6 competes with NF-,ffl (BPi)
for binding the angiotensinogen APRE. Purified
NF-KB (BPi) prepared from LPS-stimulated rat
hepatocytes was incubated with either
radiolabeled APRE (left) or NF-KB
oligonucleotides in the presence of increasing
amounts of NF-1L6. After binding, reactions
were analyzed by nondenaturing PAGE and
exposed to autoradiography. Location of
complexes produced by BPi and NF-1L6 are
indicated. With increasing amounts of NF-1L6,
the abundance of BPi complexes is diminished
only on the APRE DNA template, indicating
DNA-specific competition for binding. (Right).
Overexpression of NF-1L6 blocks NF-gB
mediated transcription. HepG2 cells were
transiently transfected with angiotensinogen
luciferase reporters in the absence or presence
of NF-1L6 expression vectors. After 40 hours of
transfection, cells in the indicated lanes were
stimulated with recombinant IL-i for 4 hours.
Luciferase reporter activity was measured and
normalized to internal control alkaline
phosphatase reporter activity. NF-1L6
expression attenuates the IL-i activated, NF-KB
mediated transcription of the angiotensinogen
APRE.
the potent transactivating subunit of the NF-KB family, interacts
with the APRE has been lacking.
NF-,..-B p6.5 subunit transactivates the APRE
Transient transfection-overexpression assays are used as sensi-
tive measures to determine whether a cloned transcription factor
can regulate the activity of a test enhancer [11]. Transfection of a
multimeric APRE-driven luciferase reporter plasmid in the pres-
ence of a eukaryotic expression vector lacking or containing
coding sequences for the human p65 subunit was performed in the
human HepG2 hepatoblastoma cell line. Luciferase activity in
transfectants containing the p65 expression vector was increased
in a dose-dependent fashion to a maximum of 50-fold stimulation.
These data, taken in combination with the ability of p65 antibod-
ies to supershift the TNF-inducible BPi DNA-binding complexes,
argues that NF-KB p65 binds and transactivates the APRE in vivo.
These data strengthen the premise that BPi is indeed NF-KB.
Nuclear Factor-1L6 also binds and transactivates the APRE
The APRE-binding heat-stable nuclear proteins termed BPc
were identified to be members of the CCAAT-box/Enhancer
Binding Protein (CIEBP) family by the following criteria: ability to
cross-compete BPc-APRE binding with CIEBP binding sites,
ability of BPc to heterodimerize with recombinant C/EBP pep-
tides in solution, and the observation that anti-CJEBP antiserum
cross-reacts with BPc peptides [5].
C/EBP proteins are nuclear DNA-binding proteins containing a
highly conserved basic domain-leucine zipper (bZIP) motif. Al-
though initially termed BPc for finding proteins constitutive, we
subsequently demonstrated that individual C/EBP family mem-
bers are regulated by acute-phase inflammation. One C!EBP
family member in particular, termed nuclear factor-1L6 (NF-1L6,
also referred to as C/EBPI3, 1L6-DBP, CRP-2, and AGP-EBP), is
the major APRE binding protein within eight hours after induc-
tion of the acute-phase response in vivo.
To study the interaction of NF-1L6 with APRE-DNA, we
achieved high levels of expression of recombinant NF-1L6 using
an E. coli T7 promoter/polymerase-based expression system [12].
Using homogeneous recombinant NF-1L6, we observed that
NF-1L6 binds to the APRE in a sequence-specific fashion by
DNase I and gel mobility shift analyses. Transient transfection of
trimeric APRE binding sites linked to a minimal angiotensinogen
promoter-luciferase reporter in the presence of a eukaryotic
expression vector for NF-1L6 produces a 40-fold activation of
luciferase reporter activity. These data indicate that NF-1L6, too,
regulates APRE enhancer activity.
Distinct temporal profiles for NF-,cB and NF-1L6 induction
Both NF-KB and NF-1L6, distinct DNA-binding proteins from
unrelated transcription factor families, are induced by acute-
phase inflammation. However, the temporal profile for their
appearance is distinct. NF-KB, a preformed DNA-binding protein
sequestered in the cytoplasm of unstimulated hepatocytes, is
induced in the nucleus within two hours after induction of
inflammation. By contrast, NF-1L6 is found at low levels in
unstimulated hepatic nuclei and its levels peak at eight hours after
initiation of inflammation. During the evolution of the acute-
phase response, both NF-KB and NF-1L6 reside in the nucleus.
What is the mechanism of their interaction on the APRE and are
there transcriptional consequences?
NF-1L6 competitively displaces NF-i.B from the APRE
Investigation of the interaction of NF-KB and NF-1L6 was
approached using purified BPi and recombinant NF-1L6 in gel
shift assays. In the assay shown in Figure 1, increasing amounts of
NF-1L6 was added to the APRE probe in the presence of a
constant amount of BPi (NF-KB) protein. With increasing con-
centrations of NF-1L6, competition for the APRE was observed in
vitro, but not observed when equal concentrations of recombinant
protein were incubated with a DNA probe that binds only NF-KB.
These results indicate that NF-KB and NF-1L6 occupy the APRE
in a mutually exclusive fashion. To determine whether this
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Fig. 2. Sequential transcription factors occupy the APRE during the evolution of the acute-phase response. A schematic diagram of hepatocyte early (1—2
hrs) in the evolution of the acute-phase response on the left, and later (8 hrs) on the right. Immediately inducible glucocorticoid receptor (GR) and
NF-KB proteins occupy the GRE and the APRE, respectively. Later, NF-1L6 de novo synthesis makes this protein the most abundant APRE binding
protein. By its ability to displace the more potent NF-icB, NF-1L6 occupies the APRE, and by virtue of being a less potent activator results in an
inhibition of further cytokine activation.
competition in vitro results in distinct transcriptional events on the
native angiotensiflOgen promoter in vivo, transient expression
assays were performed in NF-1L6 deficient HepG2 cells. In the
absence of NF-1L6, NF-KB transactivates the native angiotensino-
gen promoter in response to IL-i. In contrast, when NF-1L6 is
present, NF-KB action is blocked (Fig. 2).
Conclusions
These observations argue that during the evolution of the
inflammatory response, a sequential pattern of transcription
factors occupy the APRE. That the abundance of the NF-KB and
NF-1L6 transcription factors are regulated in a tissue-restricted
pattern may result in a distinct pattern for angiotensinogen
induction in non-hepatic tissues. Moreover, these observations
suggest that the angiotensinogen gene can be rendered inactive to
cytokine stimulation by prior stimuli that increase the abundance
of NF-1L6, and provide one mechanism to terminate NF-KB
mediated transcription of the angiotensinogen gene.
Reprint requests to Allan R. Brasier, M.D., Department of Internal
Medicine, University of Texas Medical Branch, 301 University Blvd.,
Galveston, Texas 77555-1060, USA.
References
1. BRASIER AR, PHILIPPE J, CAMPBELL DJ, HABENER JF: Novel expres-
sion of the angiotensinogen gene in a rat pancreatic islet cell line:
Transcriptional regulation by glucocorticoids. J Biol Chem 261:16148—
16154, 1986
2. B1tsIER AR, RON D, TATE JE, HABENER JF: Synergistic enhansons
located within an acute-phase responsive enhancer modulate glu-
cocorticoid induction of angiotensinogen gene transcription. Mol
Endocrinol 4:1921—1933, 1990
3. COEZY F, BOUI-INIK J, CLAUSER F, PINET F, PHILIPPE M, MENARD J,
CORVOL P: Effects of glucocorticoids and antiglucocorticoid on angio-
tensinogen production by hepatoma cells in culture. In Vitro 20:528—
534, 1984
4. BOUHNIK J, Svoie F, CORVOL P: Differential effects of inflammation
models on rat T-kininogen and rat angiotensinogen. Biochem Phar-
,nacol 37:1099—1102, 1988
5. Bisiat AR, RON D, TAm JE, HABENER JF: A family of constitutive
C/EBP-like DNA-binding proteins attenuate the IL-la induced,
NF-KB mediated transactivation of the angiotensinogen gene acute-
phase response element. EMBO J 9:3933—3944, 1990
6. KAGEYAMA R, OHKT.JBO H, NAK.4.NISHI S: Induction of rat liver
angiotensinogen mRNA following acute inflammation. Biophys Rio-
chem Res Corn 129:826—832, 1985
7. BRASIER AR, TAm JE, RON D, HABENER iF: Multiple cis-acting DNA
regulatory elements mediate hepatic angiotensinogen gene expres-
sion. Mol Endocrinol 3:1022—1034, 1989
8. RON D, BRASIER AR, WRIGHT KA, HABENER JF: The permissive role
of glucocorticoids on interleukin-1 stimulation of angiotensinogen
gene transcription is mediated by an interaction between inducible
enhancers. Mol Cell Biol 10:4389—4395, 1990
9. JANTEEN HM, STRAHLE U, GLOSS B, STEWART F, SCHMIO W,
BOSHART M, MIKSICEK R, SCHUTZ G: Cooperativity of glucocorticoid
response elements located far upstream of the tyrosine aminotrans-
ferase gene. Cell 49:29—38, 1987
10. BAEUERLE PA: The inducible transcription activator NF-,<B: Regula-
tion by distinct protein subunits. Biochim Biophys Acta 1072:63—80,
1991
11. Bisiei AR, RON D: Luciferase reporter gene assay in mammalian
cells. Meth Enzymol 216:386—396, 1992
12. BRASIER AR, KUMAR A: Identification of a novel determinant for
basic domain leucine zipper DNA binding activity in the acute-phase
inducible nuclear factor-1L6 transcription factor. J Biol Chem (in
press)
